Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (CVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
US Court Lets Two CVS Caremark Corporation's Stores Sell Controlled Drugs-Reuters
Reuters reported that a U.S. appeals court ruled that CVS Caremark Corporation may continue selling potentially addictive prescription drugs at two Florida pharmacies, blocking a Drug Enforcement Administration order to suspend shipments. The U.S. Court of Appeals for the District of Columbia Circuit issued an order on Wednesday temporarily lifting a February 4 DEA suspension that was issued because of concerns that CVS was not adequately watching for prescription abuse. The DEA said the two CVS pharmacies in Sanford, about 30 miles south of Orlando, were inappropriately filling prescriptions for the painkiller oxycodone, which can be highly addictive. Initially a federal district court judge blocked the DEA order but on Tuesday agreed to let it take effect. CVS appealed the decision. The appeals court in Washington on Wednesday granted CVS's request and issued a stay pending further proceedings. The court ordered CVS to file a response by March 19 and the DEA to file its response by March 21, according to the court docket.
Latest Developments for CVS Caremark Corp
- Cvs Caremark Corp Raises Low End Of Prior FY 2013 EPS Guidance To A Range In Line With Analysts' Estimates; Issues Q2 2013 EPS Guidance In Line With Analysts' Estimates
- Cvs Caremark Corp Buys Drogaria Onofre-Reuters
- Cvs Caremark Corp Raises FY 2013 EPS Guidance
- Cvs Caremark Corp Issues FY 2013 EPS Guidance In Line With Analysts' Estimates-Conference Call
- Share this
- Link this
- Digg this


Follow Reuters